The world of Kedrion Biopharma at a glance:
discover the latest
up-to-date news.

All news.
Kedrion Biopharma Extends Contract Manufacturing Agreement (CMA) for GAMMAKED in the US, Ensuring Availability to Patients
Kedrion Biopharma will continue to market and distribute GAMMAKED in the U.S. through end of 2025
Read all
Kedrion Biopharma to commercialize RYPLAZIM® in U.S
RYPLAZIM® (plasminogen, human-tvmh) will address needs in patients with ultra-rare condition Plasminogen Deficiency Type 1
Read all
Kedrion grows in North America as it completes acquisition of Prometic
Launch is planned for the first ever FDA-approved treatment for patients suffering from Congenital Plasminogen Deficiency
Read all